This approval affects clinicians caring for pediatric patients with Menkes disease and pediatric patients with a confirmed diagnosis of Menkes disease, including those identified in the newborn period; the specific clinician specialties were not reported in the provided source excerpts. The source-confirmed trial data support that initiation of ZYCUBO within 4 weeks of birth is associated with a 78% reduction in the risk of death versus an external control cohort, and the label specifies age-based subcutaneous dosing and serial laboratory monitoring for copper, electrolytes, kidney and liver function, and CBC ^[4][3]. What are the long-term survival and safety outcomes beyond the trial follow-up and how should monitoring be optimized long term?

Q1 What is ZYCUBO (copper histidinate) approved for?

ZYCUBO is approved for the treatment of Menkes disease in pediatric patients. The label specifies that ZYCUBO is a copper replacement product indicated for Menkes disease in pediatric patients and that it is not indicated for the treatment of Occipital Horn Syndrome. The approval was supported by survival analyses from two open-label clinical trials compared with an external control cohort. Clinicians should consult current prescribing information for complete dosing guidance.

Q2 How does ZYCUBO work?

ZYCUBO is a bioavailable copper replacement therapy administered subcutaneously to bypass impaired gastrointestinal copper absorption in patients with Menkes disease. The prescribing information explains that Menkes disease is caused by pathogenic variants in ATP7A leading to impaired copper absorption and transport, and that subcutaneous copper histidinate delivers bioavailable copper systemically to address that deficiency. Clinicians should consult current prescribing information for complete dosing guidance.

Q3 What is the recommended dose of ZYCUBO?

The FDA-approved dosing in pediatric patients is: for patients less than 1 year of age, 1.45 mg administered subcutaneously twice daily (8–12 hours between injections); for patients 1 year to less than 17 years of age, 1.45 mg administered subcutaneously once daily. The product is supplied as a 2.9 mg vial (equivalent to 0.5 mg elemental copper) that is reconstituted and administered subcutaneously; the label includes specific preparation, storage, and administration instructions. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the most common side effects of ZYCUBO?

The most common adverse reactions (incidence ≥7%) reported in the pooled safety analysis included pneumonia, viral infection, respiratory failure, seizure, bacterial infection, hemorrhage, hypotension, vomiting, tachycardia, pyrexia, volume depletion, fracture, dyspnea, transaminases elevation, diarrhea, fungal infection, anemia, and local administration reaction. The label also warns about copper accumulation with potential drug-induced kidney injury, liver dysfunction, and hematological abnormalities and provides monitoring guidance for serum copper and ceruloplasmin, electrolytes, kidney and liver function, and complete blood count. Clinicians should consult current prescribing information for complete dosing guidance.